Siemens - Molecular Imaging Solutions
Siemens Medical Solutions has introduced a range of molecular imaging solutions for the fields of Cardiology, Oncology and Neurology. Molecular medicine is expected to help physicians detect diseases earlier, and more importantly, to forecast the effectiveness of drugs for a patient and determine the best therapy on a personalized basis.
The various solutions introduced by Siemens at the 2006 Society of Nuclear Medicine Annual Meeting (SNM), held June 4-7 in San Diego are as follows:
Biograph™ PET-CT Symbia® SPECT-CT
TruePoint™ PET-CT
vertebral marrow clinical image Oncology ― Hybrid imaging solutions such as the Biograph™ family of PET•CT systems and the Symbia® family of SPECT•CT scanners produce true clarity with unmatched image quality and resolution, offering enhanced diagnostic confidence from initial diagnosis to therapy planning, staging and follow-up. Siemens’ new TruePoint™ PET•CT platform will provide dramatic improvements in the clinical capabilities of PET•CT. In addition, Siemens provides hybrid imaging software suites such as the syngo® MultiModality Workplace, which offers intuitive post processing and advanced visualization.
c.cam™Cardiology ― Siemens’ cardiology solutions, including c.cam™, e.cam®, Symbia SPECT, Symbia SPECT•CT, and Biograph PET•CT systems provide cardiologists with functional information such as wall motion, myocardial perfusion, and in some cases plaque characterization, as well as morphological information, such as the presence of coronary calcifications and detailed cardiac anatomy. New workflow enhancements to the Symbia line of hybrid imagers include automatic and integrated collimator changing options, as well as an automatic quality control option that automates all daily, weekly and monthly quality control needs of the system.
syngo® cardio fusion screen
Neurology ― Siemens syngo Scenium facilitates neurological evaluation by enabling automatic correlation of a patient study with an average brain for assessment of abnormalities. Other advancements include imaging biomarkers that will help physicians detect both ß-amyloid plaques and neuronal Tangles to predict the onset of dementia and neurological disorders – often before symptoms appear. This will not only facilitate earlier treatment, but also the development of better drugs that effectively manage the progression of disease.
